Navigation Links
Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
Date:9/24/2013

MOUNTAIN VIEW, Calif., Sept. 24, 2013 /PRNewswire/ -- Edison Pharmaceuticals announced today initiation of a phase 2 clinical trial titled "Therapeutic Trial of EPI-743 in Patients with Disorders of Energy Utilization or Oxidation-Reduction."

The trial is a double-blind, placebo-controlled crossover study in which subjects will receive either EPI-743 treatment or placebo for six months. They will then be crossed over to the other arm (treatment or placebo). Eligible subjects must possess defined or undefined genetic diagnoses that feature cellular oxidation/reduction or energy production defects.

Those children absent a genetic diagnosis will be recruited through the National Institutes of Health (NIH) Undiagnosed Diseases Program (UDP). The principle enrollment criterion stipulates that all subjects must have a neuromuscular disorder of suspected mitochondrial or metabolic etiology. All subjects will also be enrolled in a clinical trial studying the natural history of metabolic disorders. Prior to enrollment, patient cells will be analyzed in the laboratory to verify that the cells display biochemical abnormalities associated with mitochondrial disease and can be rescued by EPI-743. 

The primary endpoints in this study are improvement in disease severity and quality of life as measured by the Newcastle Pediatric Mitochondrial Disease Scale. Secondary outcome measures include neuromuscular function and disease-related biochemical markers. More information on study specifics is available on www.ClinicalTrials.gov.

Of the approximately 4 million children born each year in the United States, an estimated 4,000 will have a mitochondrial disease. However, this may be an underestimation of true disease prevalence, since many pediatric neuromuscular patients present with laboratory and clinical findings consistent with energy or mitochondrial dysfunction absent a genetic diagnosis. The objective of the study is to evaluate responsiveness to EPI-743, including subjects who do not possess a genetic diagnosis.

"This is a pioneering study for the National Human Genome Research Institute (NHGRI)," said NHGRI Clinical Director William Gahl, MD, PhD, who also is director of the UDP. "If successful, it will offer the potential for treatment for clinically devastating pediatric neurological disorders. The study can also provide diagnostic clues regarding the causes of rare and undiagnosed diseases."

UDP was started in 2008 to address the unmet medical need of patients with complex, multisystem disorders. Details of the program and its accomplishments were recently reported in Genetics in Medicine (The National Institutes of Health Undiagnosed Diseases Program: Insights into rare disease, 2012;13:51-59).  The UDP multidisciplinary team combines sophisticated cutting-edge basic science and molecular diagnostic techniques with high-level clinical care to provide diagnoses and therapies for patients with previously undiagnosed diseases.

Edison Pharmaceuticals
Edison Pharmaceuticals is a biotechnology company dedicated to developing treatments for children and adults with mitochondrial diseases. More information can be found at www.edisonpharma.com.


'/>"/>
SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Edison initiates coverage of Derma Sciences
2. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
3. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
4. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
5. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
6. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
7. Edison Pharmaceuticals Closes $20M Series F Financing
8. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
10. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
11. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  ...  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Positron Emission Tomography (PET) scanner and cyclotron install base in ... France , Germany , ... the United Kingdom . Along with the ...
(Date:5/5/2016)... May 5, 2016 ... the  "Europe Thalassaemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights - 2016, ... Thalassaemia epidemiology, Thalassaemia market valuations and forecast, ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... Canadian author Mark Black is a speaker, author, ... the Heart" around the world … with the help of his publisher Strategic Book Group ... Black lay in a hospital bed waiting for a miracle: He needed a heart and ...
(Date:5/6/2016)... ... ... Multiple award winning plumbing company in San Diego, Bill Howe ... values of exceptional customer service, quality work at reasonable rates, and giving back to ... Diego plumbing, and other services including heating & air conditioning and restoration & flood ...
(Date:5/6/2016)... ... 2016 , ... In honor of Military Spouse Appreciation Day ... the National Military Family Association, a nonprofit that works to strengthen and protect ... recipient of 2016. , “Being awarded this scholarship by Career Step, is ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
Breaking Medicine News(10 mins):